All Posts

LAG 3 - The Future of Cancer Immunotherapy
LAG 3: A Promising Next Generation Cancer Immunotherapy

Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer. Cancer immunotherapy (CI) is recently advancing at a rapid pace and can be considered as the “fifth pillar” of cancer treatment, joining the ranks of radiation, cytotoxic chemotherapy, ...

Find More

Treatment-resistant Hypertension Market Analysis and Emerging Therapies
Treatment-resistant Hypertension: Insights into the Challenges and Solutions

Resistant Hypertension (RHTN) is defined as uncontrolled blood pressure despite the use of ≥3 antihypertensive agents of different classes, including a diuretic, usually thiazide-like, a long-acting calcium channel blocker, and a blocker of the renin-angiotensin system, either an ACE (angiotensin-converting enzyme)...

Find More

MedTech News for Ypsomed Fresenius Kabi Sientra Synchron HLT
Ypsomed-CamDiab’s Collaboration; Vela Diagnostics’s NGS-Based Pan-Cancer Panels; Fresenius’s SMOFlipid Lipid Injectable Emulsion; Sientra Gained Regulatory Nod to Market Breast Implants; Synchron’s Endovascular BCI Stentrode Device; HLT’s TAVR Clinical Studies

Ypsomed Collaborated with CamDiab for Smartphone-based Automated Insulin Delivery On March 22, 2022, Ypsomed, a leading manufacturer of injection and infusion systems for self-medication partnered with CamDiab Ltd, developer of CamAPS FX, an app for the management of glucose levels via insulin pumps using an ada...

Find More

Top Drugs Losing Patent Protection in 2022
Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022

Patent protection and expiration is one of the hot topics in the healthcare industry. Patent protection results in high sales and profits for the initial developers and innovators of the drugs, and as per various estimates, the gross profit margins for the Patent protected drugs exceed 90% in some cases. However, t...

Find More

Pharma News and Updates for Sanofi ViiV Argenx Novartis UCB Kyowa
Sanofi’s Rare Disease Drug Xenpozyme’ Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB’s FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval

Sanofi’s Rare Disease Drug Xenpozyme Wins World’s First Approval in Japan Sanofi’s Xenpozyme, also known as olipudase alfa, the world's first therapy for the rare disease Niemann-Pick type A/B and B, has been approved for the treatment of children and adults with non-CNS manifestations of Acid Sphingomyelinase D...

Find More

Fabry Disease Treatment Landscape
Examining the Therapeutic Advances in Fabry Disease Treatment Landscape

Fabry Disease is an inherited lysosomal storage disease caused by a nonfunctional or partially functional enzyme called alpha galactosidase A (α-Gal A). Decreased activity of α-Gal A in lysosomes results in the accumulation of enzyme substrates (Gb3 and lyso-Gb3) which cause cellular damage in tissues throughout th...

Find More

dupixent-market
Can Dupixent Be A Gamechanger In The Atopic Dermatitis Treatment Landscape?

Dupixent (dupilumab) is a non-immunosuppressive fully human monoclonal antibody that inhibits the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. According to data from Dupixent clinical trials, IL-4 and IL-13 are key drivers of type 2 inflammation, which is a major contributor to Atopic...

Find More

MedTech News for Smithfield, Cynosure, bioMérieux, Artio Medical, HeartPoint, ObvioHealth
Smithfield BioScience and BioCircuit’s Nerve Tape Device; Cynosure-Jeisys Medical’s Partnership; bioMérieux’s VITEK® MS PRIME new MALDI-TOF Mass Spectrometry Identification System; Artio Medical’s Gold Embolization Device; Heartpoint Global’s Implant System; ObvioHealth’s Virtual Urogynecology Clinical Trial

Smithfield BioScience and BioCircuit to Develop New Nerve Tape Device On March 16, 2022, BioCircuit Technologies, a National Institutes of Health (NIH)-funded medical device company primarily focused on developing and commercializing tissue repair and neural interfacing products, and Smithfield BioScience, a uni...

Find More

Top 10 Most Common Food Allergies
What are the Top 9 Most Common Food Allergies and How Pharma Companies are Tackling the Crisis?

Food Allergies is a major concern for a wide spectrum of populations globally. According to the World Allergy Organization, “food allergy affected approximately 2.5% of the general population, but the spread of prevalence data was wide, ranging from 1% to 10%.” According to the Centers for Disease Control and Preve...

Find More

Pharma News and Updates for BMS, Biogen, Merck, Moderna, and Takeda
Bristol Myers’ Opdivo combo Opdualag for Melanoma; Biogen’s Aduhelm; Marinus’ Ztalmy for CDKL-5 Deficiency Disorder; Merck’s Keytruda + Lynparza; Vitaris’s Breyna; Moderna’s Second COVID-19 Booster Shot; Takeda’s Exkivity; BMS’s First LAG-3 Checkpoint Inhibitor

NHS Grants Fast Track Access to Takeda’s Exkivity Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks. The Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorisa...

Find More